36,426 Results

Phase III TIMES 2 trial of imeglimin shows positive results in type 2 diabetes.- Poxel/Sumitomo Dainippon Pharma

 Added 16 hours ago

POXEL and Sumitomo Dainippon Pharma announced positive topline results from TIMES 2, a Phase III trial evaluating imeglimin in combination...

Phase III MMPOWER-3 trial of Ocuvia fails to meet endpoint in primary mitochondrial myopathy.- Stealth BioTherapeutics

 Added 16 hours ago

Stealth BioTherapeutics announced top-line data from the Phase III MMPOWER-3 trial evaluating Ocuvia (elamipretide) for treatment of patients with primary...

Sorrento Therapeutics rejects takeover offer.

 Added 16 hours ago

Sorrento Therapeutics, Inc. announced that, after reviewing the latest acquisition proposal in consultation with its advisors, Sorrento’s Board of Directors...

Kissei announces the publication of the results of phase III trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry;

 Added 16 hours ago

Kissei Pharmaceutical Co., Ltd. announced that the results of two phase III clinical trials of rovatirelin discoverd by Shionogi &...

Vibegron filed with FDA for overactive bladder.- Urovant Sciences

 Added 16 hours ago

Urovant Sciences has submitted a New Drug Applicationto the FDA seeking approval of once-daily 75mg vibegron for the treatment of...

Phase II registrational trial of Enhertu to treat HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer . AstraZeneca + Daiichi Sankyo

 Added 16 hours ago

High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca’s and Daiichi Sankyo Company, Limited 's Enhertu (trastuzumab...

Top-line results from phase III study (BREEZE-AD4) of baricitinib with topical corticosteroids in patients with moderate to severe atopic dermatitis not controlled with cyclosporine.- Eli Lilly

 Added 16 hours ago

Eli Lilly and Company and Incyte announced that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase III, randomized,...

European Commission approves use of Stelara in paediatric patients with plaque psoriasis. Johnson & Johnson

 Added 16 hours ago

Johnson & Johnson announced that the European Commission (EC) has approved the label expansion of Stelara (ustekinumab) for the treatment...

AstraZeneca recovers rights to brazikumab from Allergan.

 Added 16 hours ago

AstraZeneca will recover the global rights to brazikumab (formerly MEDI 2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is...

Load more